Meredith S Duncan1,2, Matthew S Freiberg1,3,4, Robert A Greevy3,5, Suman Kundu1, Ramachandran S Vasan6,7,8, Hilary A Tindle3,4,9. 1. Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Division of Epidemiology, Vanderbilt University, Nashville, Tennessee. 3. Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee. 4. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Sections of Preventive Medicine and Epidemiology and Cardiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts. 7. Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts. 8. Boston University and NHLBI Framingham Heart Study, Framingham, Massachusetts. 9. Division of General Internal Medicine and Public Health, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
Importance: The time course of cardiovascular disease (CVD) risk after smoking cessation is unclear. Risk calculators consider former smokers to be at risk for only 5 years. Objective: To evaluate the association between years since quitting smoking and incident CVD. Design, Setting, and Participants: Retrospective analysis of prospectively collected data from Framingham Heart Study participants without baseline CVD (original cohort: attending their fourth examination in 1954-1958; offspring cohort: attending their first examination in 1971-1975) who were followed up through December 2015. Exposures: Time-updated self-reported smoking status, years since quitting, and cumulative pack-years. Main Outcomes and Measures: Incident CVD (myocardial infarction, stroke, heart failure, or cardiovascular death). Primary analyses included both cohorts (pooled) and were restricted to heavy ever smokers (≥20 pack-years). Results: The study population included 8770 individuals (original cohort: n = 3805; offspring cohort: n = 4965) with a mean age of 42.2 (SD, 11.8) years and 45% male. There were 5308 ever smokers with a median 17.2 (interquartile range, 7-30) baseline pack-years, including 2371 heavy ever smokers (406 [17%] former and 1965 [83%] current). Over 26.4 median follow-up years, 2435 first CVD events occurred (original cohort: n = 1612 [n = 665 among heavy smokers]; offspring cohort: n = 823 [n = 430 among heavy smokers]). In the pooled cohort, compared with current smoking, quitting within 5 years was associated with significantly lower rates of incident CVD (incidence rates per 1000 person-years: current smoking, 11.56 [95% CI, 10.30-12.98]; quitting within 5 years, 6.94 [95% CI, 5.61-8.59]; difference, -4.51 [95% CI, -5.90 to -2.77]) and lower risk of incident CVD (hazard ratio, 0.61; 95% CI, 0.49-0.76). Compared with never smoking, quitting smoking ceased to be significantly associated with greater CVD risk between 10 and 15 years after cessation in the pooled cohort (incidence rates per 1000 person-years: never smoking, 5.09 [95% CI, 4.52-5.74]; quitting within 10 to <15 years, 6.31 [95% CI, 4.93-8.09]; difference, 1.27 [95% CI, -0.10 to 3.05]; hazard ratio, 1.25 [95% CI, 0.98-1.60]). Conclusions and Relevance: Among heavy smokers, smoking cessation was associated with significantly lower risk of CVD within 5 years relative to current smokers. However, relative to never smokers, former smokers' CVD risk remained significantly elevated beyond 5 years after smoking cessation.
Importance: The time course of cardiovascular disease (CVD) risk after smoking cessation is unclear. Risk calculators consider former smokers to be at risk for only 5 years. Objective: To evaluate the association between years since quitting smoking and incident CVD. Design, Setting, and Participants: Retrospective analysis of prospectively collected data from Framingham Heart Study participants without baseline CVD (original cohort: attending their fourth examination in 1954-1958; offspring cohort: attending their first examination in 1971-1975) who were followed up through December 2015. Exposures: Time-updated self-reported smoking status, years since quitting, and cumulative pack-years. Main Outcomes and Measures: Incident CVD (myocardial infarction, stroke, heart failure, or cardiovascular death). Primary analyses included both cohorts (pooled) and were restricted to heavy ever smokers (≥20 pack-years). Results: The study population included 8770 individuals (original cohort: n = 3805; offspring cohort: n = 4965) with a mean age of 42.2 (SD, 11.8) years and 45% male. There were 5308 ever smokers with a median 17.2 (interquartile range, 7-30) baseline pack-years, including 2371 heavy ever smokers (406 [17%] former and 1965 [83%] current). Over 26.4 median follow-up years, 2435 first CVD events occurred (original cohort: n = 1612 [n = 665 among heavy smokers]; offspring cohort: n = 823 [n = 430 among heavy smokers]). In the pooled cohort, compared with current smoking, quitting within 5 years was associated with significantly lower rates of incident CVD (incidence rates per 1000 person-years: current smoking, 11.56 [95% CI, 10.30-12.98]; quitting within 5 years, 6.94 [95% CI, 5.61-8.59]; difference, -4.51 [95% CI, -5.90 to -2.77]) and lower risk of incident CVD (hazard ratio, 0.61; 95% CI, 0.49-0.76). Compared with never smoking, quitting smoking ceased to be significantly associated with greater CVD risk between 10 and 15 years after cessation in the pooled cohort (incidence rates per 1000 person-years: never smoking, 5.09 [95% CI, 4.52-5.74]; quitting within 10 to <15 years, 6.31 [95% CI, 4.93-8.09]; difference, 1.27 [95% CI, -0.10 to 3.05]; hazard ratio, 1.25 [95% CI, 0.98-1.60]). Conclusions and Relevance: Among heavy smokers, smoking cessation was associated with significantly lower risk of CVD within 5 years relative to current smokers. However, relative to never smokers, former smokers' CVD risk remained significantly elevated beyond 5 years after smoking cessation.
Authors: Caroline S Fox; Jane C Evans; Martin G Larson; Donald M Lloyd-Jones; Christopher J O'Donnell; Paul D Sorlie; Teri A Manolio; William B Kannel; Daniel Levy Journal: Am J Cardiol Date: 2005-04-01 Impact factor: 2.778
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Gang Liu; Yang Hu; Geng Zong; An Pan; JoAnn E Manson; Kathryn M Rexrode; Eric B Rimm; Frank B Hu; Qi Sun Journal: Lancet Diabetes Endocrinol Date: 2020-01-07 Impact factor: 32.069
Authors: Yunfeng Huang; Qin Hui; Marta Gwinn; Yi-Juan Hu; Arshed A Quyyumi; Viola Vaccarino; Yan V Sun Journal: Genet Epidemiol Date: 2022-02-16 Impact factor: 2.135
Authors: Mi Jung Lee; Jung Tak Park; Tae Ik Chang; Young Su Joo; Tae-Hyun Yoo; Sue Kyung Park; Wookyung Chung; Yong-Soo Kim; Soo Wan Kim; Kook-Hwan Oh; Shin-Wook Kang; Kyu Hun Choi; Curie Ahn; Seung Hyeok Han Journal: Clin J Am Soc Nephrol Date: 2021-04-20 Impact factor: 10.614
Authors: Jose Gutierrez; Farid Khasiyev; Minghua Liu; Janet T DeRosa; Sarah E Tom; Tatjana Rundek; Ken Cheung; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind Journal: J Am Coll Cardiol Date: 2021-08-10 Impact factor: 27.203